First PCSK9 inhibitors approved in Europe and United States The US Food and Drug Administration has approved alirocumab (Praluent), days after evolocumab (Repatha) became the first PCSK9 inhibitor to be approved in the world.…
Clinical Pharmacist’s monthly news round-up: the top 10 in the past month What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month.…
Attacking cancer: are therapeutic vaccines on the verge of fulfilling their potential? Researchers are investigating whether priming the immune system with therapeutic vaccines can prompt the body’s own defences to spring into action against cancer.…
FDA approves brexpiprazole for schizophrenia and depression The US Food and Drug Administration has approved brexpiprazole for the treatment of adults with schizophrenia and as add-on therapy in patients with major depressive disorder.…
Cystic fibrosis therapy approved by US Food and Drug Administration A combination therapy of two drugs that target the most common genetic mutation responsible for cystic fibrosis has been given a licence in the United States.…
Investigating dietary supplements and the industry ‘Vitamania: our obsessive quest for nutritional perfection’ by Catherine Price.…
Cangrelor approved for use in the United StatesCangrelor has been approved for use in adult patients undergoing percutaneous coronary intervention in the United States, following a decision by the US Food and Drug Administration.…
Global crackdown on illegal internet trade yields £51.6m worth of medicines and devices An international crackdown on the illegal internet trade in medicines has yielded £51.6m worth of items from 115 different countries.…
Repositioning existing drugs for cancer treatment Scientists are using systematic approaches to identify non-oncology drugs that can be used to treat cancer, but access to drugs and commercial challenges are hindering progress.…